Table 1. Demographic characteristics, tumor pathology, and clinical staging of 34 patients with DLBCL or FL.
| Characteristics | DLBCL (n = 23) | FL (n = 11) | Total (n = 34) |
| Age (years) | |||
| mean | 64 | 60 | 63 |
| range | 32–86 | 43–77 | 32–86 |
| gender | |||
| female | 9 | 8 | 17 |
| male | 14 | 3 | 17 |
| Histology | 23 DLBCL | 10 FL II, 1 FL III | 34 |
| Ann Arbor stage | |||
| I | 1 | 0 | 1 |
| II | 5 | 1 | 6 |
| III | 5 | 7 | 12 |
| IV | 12 | 3 | 15 |
| IPI or FLIPI* | |||
| 0–1 | 5 | 0 | 5 |
| 2 | 7 | 5 | 12 |
| 3 | 8 | 4 | 12 |
| 4 | 3 | 2 | 5 |
| Target tumor site | |||
| abdomen | 10 | 6 | 16 |
| neck | 8 | 1 | 9 |
| upper thigh | 3 | 1 | 4 |
| thorax | 2 | 1 | 3 |
| pelvis | 0 | 2 | 2 |
IPI (International Prognostic Index) was used for the evaluation of DLBCL. IPI 1: low risk; IPI 2: low-intermediate risk; IPI 3: high-intermediate risk; IPI 4: high risk. * FLIPI (Follicular Lymphoma International Prognostic Index) was used for FL. FLIPI 0–1: low risk; FLIPI 2: intermediate risk; FLIPI≥3: high risk.